Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
August 19, 2025Frontiers in OncologyOpen Access

Real-world Australian experience with tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma—importance of pre-CAR-T optimization

View Full Paper
Ask AI
Bookmark
Share

Authors

PHPhoebe Joy HoVVVinay VanguruCBC. Burge

Discussion

Loading...

Member takes

Overview

Analysis highlights the importance of bridging therapy and pre-CAR-T optimization in patients with r/r diffuse large B-cell lymphoma.

Key Points

  • The overall response rate for patients treated with tisagenlecleucel was 79%, with 60% achieving complete response.
  • High lactate dehydrogenase at infusion was associated with a significantly higher risk of disease progression and death.
  • Almost one-third of patients normalizing lactate dehydrogenase before infusion had better progression-free survival rates.
  • Bridging therapy prior to CAR-T treatment is crucial for optimizing patient outcomes and improving response rates.

Cite This Study

Ho et al. (2025) studied this question.

synapsesocial.com/papers/68af31efcf1dd9ea359e835fhttps://doi.org/10.3389/fonc.2025.1633644
View Full Paper
Ask AI
Bookmark
Share